VCYT insider sells 43,196 shares after option exercises; 30,468 owned
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Veracyte, Inc. (VCYT) reported an insider transaction by a director. On 11/05/2025, the insider exercised stock options for 30,000 shares at exercise prices of $5.28, $7.94, and $7.60, then sold 43,196 shares in multiple trades at weighted average prices ranging from $41.10 to $46.40. These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2024.
Following the transactions, the insider directly beneficially owns 30,468 shares. The options exercised were fully vested, tied to grants expiring on 06/20/2026, 06/07/2027, and 06/07/2028.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 43,196 shares ($1,946,288)
Net Sell
12 txns
Insider
JONES EVAN/ FA
Role
Director
Sold
43,196 shs ($1.95M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 10,000 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 10,000 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $5.28 | $53K |
| Exercise | Common Stock | 10,000 | $7.94 | $79K |
| Exercise | Common Stock | 10,000 | $7.60 | $76K |
| Sale | Common Stock | 408 | $41.7431 | $17K |
| Sale | Common Stock | 1,126 | $43.0329 | $48K |
| Sale | Common Stock | 10,837 | $43.8038 | $475K |
| Sale | Common Stock | 5,872 | $45.0682 | $265K |
| Sale | Common Stock | 24,296 | $45.7273 | $1.11M |
| Sale | Common Stock | 657 | $46.3756 | $30K |
Holdings After Transaction:
Stock Option (right to buy) — 0 shares (Direct);
Common Stock — 53,664 shares (Direct)
Footnotes (1)
- The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 9, 2024. Represents weighted average sales price. Sale prices for the transactions range from $41.10 to $41.97. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $42.285 to $43.20. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $43.29 to $44.29. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $44.335 to $45.335. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $45.34 to $44.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Represents weighted average sales price. Sale prices for the transactions range from $46.35 to $46.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. The option is fully vested.
FAQ
What insider activity did VCYT report on 11/05/2025?
A director exercised options for 30,000 shares and sold 43,196 shares in multiple transactions on 11/05/2025.
How many Veracyte options were exercised and at what prices?
Options for 30,000 shares were exercised at $5.28, $7.94, and $7.60.
Was the VCYT insider trading under a 10b5-1 plan?
Yes. The trades were made under a Rule 10b5-1 plan adopted on December 9, 2024.
What are the expiration dates of the exercised VCYT option grants?
The related grants carry expirations on 06/20/2026, 06/07/2027, and 06/07/2028.